Eisai Co., Ltd. (ESALF)
- Previous Close
38.71 - Open
38.71 - Bid --
- Ask --
- Day's Range
38.71 - 38.71 - 52 Week Range
37.53 - 81.03 - Volume
570 - Avg. Volume
633 - Market Cap (intraday)
11.297B - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
37.58 - EPS (TTM)
1.03 - Earnings Date --
- Forward Dividend & Yield 1.06 (2.73%)
- Ex-Dividend Date Mar 28, 2024
- 1y Target Est
75.99
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
www.eisai.co.jp11,076
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ESALF
Performance Overview: ESALF
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ESALF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ESALF
Valuation Measures
Market Cap
11.30B
Enterprise Value
10.53B
Trailing P/E
37.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.29
Price/Book (mrq)
2.10
Enterprise Value/Revenue
0.01
Enterprise Value/EBITDA
0.09
Financial Highlights
Profitability and Income Statement
Profit Margin
6.06%
Return on Assets (ttm)
3.03%
Return on Equity (ttm)
5.70%
Revenue (ttm)
749.46B
Net Income Avi to Common (ttm)
45.42B
Diluted EPS (ttm)
1.03
Balance Sheet and Cash Flow
Total Cash (mrq)
285.19B
Total Debt/Equity (mrq)
19.73%
Levered Free Cash Flow (ttm)
16.99B
Research Analysis: ESALF
Company Insights: ESALF
ESALF does not have Company Insights